Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Tarek Nafee (talk | contribs) |
||
Line 56: | Line 56: | ||
! rowspan="3" |Diseases | ! rowspan="3" |Diseases | ||
! rowspan="3" |Mode of Inheritance | ! rowspan="3" |Mode of Inheritance | ||
! colspan=" | ! colspan="8" |Laboratory Findings | ||
! rowspan="3" |Other Findings | ! rowspan="3" |Other Findings | ||
! rowspan="3" |Management | ! rowspan="3" |Management | ||
Line 63: | Line 63: | ||
|- | |- | ||
! colspan="5" |Lipid Profile | ! colspan="5" |Lipid Profile | ||
! | ! colspan="3" |Other Laboratory Findings | ||
|- | |- | ||
!Total Cholesterol | !Total Cholesterol | ||
Line 70: | Line 70: | ||
!Triglycerides | !Triglycerides | ||
!Plasma Appearance | !Plasma Appearance | ||
!Chylomicrons | |||
!VLDL | |||
!Genetic mutations | |||
|- | |- | ||
| rowspan="6" |'''Primary Hyperlipoprotenemia''' | | rowspan="6" |'''Primary Hyperlipoprotenemia''' | ||
Line 79: | Line 82: | ||
|'''↑↑↑↑''' | |'''↑↑↑↑''' | ||
|Creamy | |Creamy | ||
| | |||
| | |||
|LPL gene mutation | |LPL gene mutation | ||
|Chylomicrons | |Chylomicrons | ||
Elevated | Elevated | ||
| | | | ||
|<nowiki>-Recurrent Pancreatitis</nowiki> | |<nowiki>-Recurrent Pancreatitis</nowiki> | ||
Line 90: | Line 95: | ||
|- | |- | ||
|Type IIA | |Type IIA | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 103: | Line 110: | ||
|- | |- | ||
|Type IIB | |Type IIB | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 116: | Line 125: | ||
|- | |- | ||
|Type III | |Type III | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 129: | Line 140: | ||
|- | |- | ||
|Type IV | |Type IV | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 142: | Line 155: | ||
|- | |- | ||
|Type V | |Type V | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 156: | Line 171: | ||
| rowspan="10" |'''Secondary Hyperlipoprotenemia''' | | rowspan="10" |'''Secondary Hyperlipoprotenemia''' | ||
|Diabetes Mellitus | |Diabetes Mellitus | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 169: | Line 186: | ||
|- | |- | ||
|Alcohol Abuse | |Alcohol Abuse | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 182: | Line 201: | ||
|- | |- | ||
|Estrogen Therapy | |Estrogen Therapy | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 195: | Line 216: | ||
|- | |- | ||
|Glucocorticoid therapy | |Glucocorticoid therapy | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 208: | Line 231: | ||
|- | |- | ||
|Renal Disease | |Renal Disease | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 221: | Line 246: | ||
|- | |- | ||
|Obesity | |Obesity | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 234: | Line 261: | ||
|- | |- | ||
|High-fat diet | |High-fat diet | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 247: | Line 276: | ||
|- | |- | ||
|Poor physical activity | |Poor physical activity | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 260: | Line 291: | ||
|- | |- | ||
|Paraproteinemic disorders | |Paraproteinemic disorders | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 273: | Line 306: | ||
|- | |- | ||
|Hypothyroidism | |Hypothyroidism | ||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 21:38, 8 November 2016
Hyperlipoproteinemia Microchapters |
ACC/AHA Guideline Recommendations |
Intensity of statin therapy in primary and secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Differential Diagnosis
Diseases | Mode of Inheritance | Laboratory Findings | Other Findings | Management | Complications | Prognosis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipid Profile | Other Laboratory Findings | |||||||||||||
Total Cholesterol | LDL | HDL | Triglycerides | Plasma Appearance | Chylomicrons | VLDL | Genetic mutations | |||||||
Primary Hyperlipoprotenemia | Type I | Autosomal Recessive | Normal or ↑ | Normal | Normal | ↑↑↑↑ | Creamy | LPL gene mutation | Chylomicrons
Elevated |
-Recurrent Pancreatitis
-Rarely life threatening |
Good | |||
Type IIA | ||||||||||||||
Type IIB | ||||||||||||||
Type III | ||||||||||||||
Type IV | ||||||||||||||
Type V | ||||||||||||||
Secondary Hyperlipoprotenemia | Diabetes Mellitus | |||||||||||||
Alcohol Abuse | ||||||||||||||
Estrogen Therapy | ||||||||||||||
Glucocorticoid therapy | ||||||||||||||
Renal Disease | ||||||||||||||
Obesity | ||||||||||||||
High-fat diet | ||||||||||||||
Poor physical activity | ||||||||||||||
Paraproteinemic disorders | ||||||||||||||
Hypothyroidism |
Classification
Hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||